Fluetonitazene
Fluetonitazene is a benzimidazole derivative which is an opioid designer drug. It was patented in 2024 as a potential novel analgesic, but appeared on the illicit market at around the same time, first being identified in Germany in March 2024. It is a potent opioid agonist in vitro with similar potency to N-Desethyletonitazene.